Reports

Sale

Neuroblastoma Market Size, Share, Growth, Trends, Analysis: By Diagnosis: MIBG Scan, Imaging, Biopsy; By Treatment: Medication, Surgery, Chemotherapy, Radiation Therapy, Stem Cell Transplantation, Immunotherapy, Monoclonal Antibody Treatment; By Age Group; By End User; Regional Analysis; Supplier Landscape; 2024-2032

Neuroblastoma Market Outlook

The neuroblastoma market size is expected to grow at a CAGR of 2.4% during the forecast period of 2024-2032, driven by the increasing incidence of cancer and rising preference for personalised medicine across the major markets.

Neuroblastoma Market Overview

Neuroblastoma is an extracranial tumor, originating from neural crest progenitor cells. It has a high prevalence in children. 37% of the overall patients are infants, and around 90% of the patients are younger than 5 years of age. The United States witnesses around 650 new cases annually, with a prevalence of 1 case per 7,000 live births.

Neuroblastoma accounts for 15% of the overall pediatric cancers. Consequently, effective treatment has been a major area of attention amongst scientists, propelling the neuroblastoma market share. While the disease can occur anywhere along the sympathetic nervous system, it majorly arises in the adrenal glands. With heterogeneity in tumor grade, stage and location, treatment modalities vary across observation, surgical interventions, chemotherapy, radiation therapy and immunotherapy.

The neuroblastoma market growth is driven by rising preference and adoption of gene therapies to offer precise and personalized treatment to patients. In November 2023, researchers at the University of Texas developed a gene therapy to pre-treat neuroblastoma tumors by expanding blood vessels surrounding a tumor. The potential treatment can be used to enhance the efficacy of drugs to regress tumor size.

Neuroblastoma Market Trends

Key Trend	Impact
Surge in Clinical Trials and Research Initiatives	With a deeper understanding of human physiology and biotech associated technical advancements, targeted therapy, immunology, and personalized medicine have emerged as a promising treatment strategy.
Emphasis on Early Detection	Development of novel biomarkers and diagnostic methods, aimed at determining most effective and accurate treatment early to stop disease progression is a significant market trend.
Rising Collaborations to Drive Awareness	Collaborations among research institutions, pharmaceutical companies and non-profit organizations are contributing to neuroblastoma market value. Investments and awareness initiatives are expected to influence the market positively in coming years.
Increased Focus on Improving Quality of Life	With improvement in treatment alternatives, there is an emphasis on long-term health and prevention of tumor recurrence. This includes addressing late effects of cancer treatment such as hearing loss and developmental delays among others.

Neuroblastoma Market Segmentation

Market Breakup by Diagnosis

MIBG Scan

Imaging

Biopsy

The market segmentation by diagnosis includes MIBG scan, imaging, and biopsy. MIBG (Metaiodobenzylguanidine) scan is a nuclear medicine imaging technique that helps in tumor visualization throughout the body using a special camera. Imaging techniques include MRI, CT scans and ultrasounds. Biopsy helps in confirming the presence of cancerous cells and provides an insight into tumor type and characteristics.

Market Breakup by Treatment

Medication

Surgery

Chemotherapy

Radiation Therapy

Stem Cell Transplantation

Immunotherapy

Monoclonal Antibody Treatment

To meet the rising neuroblastoma market demand, the market segmentation addresses the treatment landscape as well. It includes medication, surgery, chemotherapy, radiation therapy, stem cell transplantation, immunotherapy, and monoclonal antibody treatment. It varies based on grade, size, and location of tumor.

Market Breakup by End Users

Hospitals

Specialty Clinics

Surgical Centers

Diagnostic Centers

Others

Market breakup by end users constitutes hospitals, specialty clinics, surgical centers, and diagnostic centers among others. Hospitals are the most prominent alternative of tumor detection amongst patients.

Market Breakup by Region

United States

EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom

Japan

China

The neuroblastoma market report covers all major markets in the regional breakup. It includes United States, EU-4 (Germany, France, Italy, and Spain), United Kingdom, Japan as well as China. United States leads the market share, owing to its well-developed infrastructure along with the presence of several key healthcare and pharmaceutical players in the region. Asia Pacific is deemed to witness substantial growth in the forecast period, which can be attributed to increasing investments to improve the healthcare infrastructure.

Neuroblastoma Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Eli Lilly and Company

Bayer AG

GE Healthcare

Beckman Coulter Inc

bioMerieux

BD Biosciences

Lonza Biologics Ltd

Sanofi S.A.

Pfizer Inc.

Cellectar Biosciences

Baxter International Inc.

APEIRON Biologics AG

United Therapeutics Corporation

Sartorious AG

MacroGenics, Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

REPORT FEATURES	DETAILS
Base Year	2023
Historical Period	2017-2023
Forecast Period	2024-2032
Scope of the Report	Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment: Diagnosis Treatment Age Group End User Region
Breakup by Diagnosis	MIBG Scan Imaging Biopsy
Breakup by Treatment	Medication Surgery Chemotherapy Radiation Therapy Stem Cell Transplantation Immunotherapy Monoclonal Antibody Treatment
Breakup by Age Group	Infants Children Adolescents
Breakup by End User	Hospitals Specialty Clinics Surgical Centers Diagnostic Centers Others
Breakup by Region	United States EU-4 and the United Kingdom Japan China
Market Dynamics	Market Drivers and Constraints SWOT Analysis Porter’s Five Forces Model Key Demand Indicators Key Price Indicators Industry Events, Initiatives, and Trends Value Chain Analysis
Supplier Landscape	Market Structure Company Profiles Financial Analysis Product Portfolio Demographic Reach and Achievements Mergers and Acquisitions Certifications
Companies Covered	Eli Lilly and Company Bayer AG GE Healthcare Beckman Coulter Inc bioMerieux BD Biosciences Lonza Biologics Ltd Sanofi S.A. Pfizer Inc. Cellectar Biosciences Baxter International Inc. APEIRON Biologics AG United Therapeutics Corporation Sartorious AG MacroGenics, Inc.

Key Queries Solved in the Neuroblastoma Market Report

How has the neuroblastoma market performed so far and how is it expected to perform in the coming years?
What are the major market trends influencing the market?
What are the market's major drivers, opportunities, and restraints?
Which regional market is expected to lead the market share in the forecast period?
Which country is expected to experience expedited growth during the forecast period?
How does the prevalence and incidence of neuroblastoma affect the market landscape?
How does the rise in the geriatric population impact the neuroblastoma market value?
What treatment type of neuroblastoma will dominate the market share?
Which diagnostic method is expected to have a high market value in the coming years?
How will the ongoing clinical trials impact the market value during the forecast period?
What are the factors driving regional disparities in neuroblastoma treatment and outcomes?
What are the current unmet needs and challenges in the market?
How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1   Preface
   1.1   Objectives of the Study
   1.2   Key Assumptions
   1.3   Report Coverage – Key Segmentation and Scope
   1.4   Research Methodology
2   Executive Summary
3   Neuroblastoma Market Overview -8 Major Markets
   3.1   Neuroblastoma Market Historical Value (2017-2023)
   3.2   Neuroblastoma Market Forecast Value (2024-2032)
4   Neuroblastoma Overview
   4.1   Guidelines and Stages
   4.2   Pathophysiology
   4.3   Screening and Diagnosis
   4.4   Therapy Pathway
5   Patient Profile
   5.1   Patient Profile Overview
   5.2   Patient Psychology and Emotional Impact Factors
   5.3   Risk Assessment and Therapy Success Rate
6   Neuroblastoma Epidemiology Analysis- 8 Major Markets
   6.1   Epidemiology Overview (2017-2032)
   6.2   8 Major Markets Epidemiology Scenario Overview (2017-2032)
   6.3   United States Neuroblastoma Epidemiology Forecast (2017-2032)
   6.4   EU-4 and United Kingdom Neuroblastoma Epidemiology Forecast (2017-2032)
       6.4.1   Germany Neuroblastoma Epidemiology Forecast (2017-2032)
       6.4.2   France Neuroblastoma Epidemiology Forecast (2017-2032)
       6.4.3   Italy Neuroblastoma Epidemiology Forecast (2017-2032)
       6.4.4   Spain Neuroblastoma Epidemiology Forecast (2017-2032)
       6.4.5   United Kingdom Neuroblastoma Epidemiology Forecast (2017-2032)
   6.5   Japan Neuroblastoma Epidemiology Forecast (2017-2032)
   6.6   China Neuroblastoma Epidemiology Forecast (2017-2032)
7   Neuroblastoma Market Landscape* - 8 Major Markets
   7.1   Neuroblastoma Developers Landscape
       7.1.1   Analysis by Year of Establishment
       7.1.2   Analysis by Company Size
       7.1.3   Analysis by Region
   7.2   Neuroblastoma Product Landscape
       7.2.1   Analysis by Diagnosis
       7.2.2   Analysis by Treatment
8   Neuroblastoma Treatment Challenges and Unmet Needs
   8.1   Treatment Pathway Challenges
   8.2   Compliance and Drop-Out Analysis
   8.3   Awareness and Prevention Gaps
9   Cost of Treatment
10   Neuroblastoma Market Dynamics
   10.1   Market Drivers and Constraints
   10.2   SWOT Analysis
   10.3   SWOT Analysis
       10.3.1   Strengths
       10.3.2   Weaknesses
       10.3.3   Opportunities
       10.3.4   Threats
   10.4   Porter’s Five Forces Model
       10.4.1   Bargaining Power of Suppliers
       10.4.2   Bargaining Power of Buyers
       10.4.3   Threat of New Entrants
       10.4.4   Threat of Substitutes
       10.4.5   Degree of Rivalry
   10.5   Key Demand Indicators
   10.6   Key Price Indicators
   10.7   Industry Events, Initiatives, and Trends
   10.8   Value Chain Analysis
11   Neuroblastoma Market (2017-2032) Segmentation-8 Major Markets
   11.1   Neuroblastoma Market (2017-2032) by Diagnosis
       11.1.1   Market Overview
       11.1.2   MIBG Scan
       11.1.3   Imaging
       11.1.4   Biopsy
   11.2   Neuroblastoma Market (2017-2032) by Treatment
       11.2.1   Market Overview
       11.2.2   Medication
       11.2.3   Surgery
       11.2.4   Chemotherapy
       11.2.5   Radiation Therapy
       11.2.6   Stem Cell Transplantation
       11.2.7   Immunotherapy
       11.2.8   Monoclonal Antibody Treatment
   11.3   Neuroblastoma Market (2017-2032) by Age Group
       11.3.1   Market Overview
       11.3.2   Infants
       11.3.3   Children
       11.3.4   Adolescents
   11.4   Neuroblastoma Market (2017-2032) by End User
       11.4.1   Market Overview
       11.4.2   Hospitals
       11.4.3   Specialty Clinics
       11.4.4   Surgical Centers
       11.4.5   Diagnostic Centers
       11.4.6   Others
   11.5   Neuroblastoma Market (2017-2032) by Region
       11.5.1   Market Overview
       11.5.2   United States
       11.5.3   EU-4 and the United Kingdom
           11.5.3.1   Germany
           11.5.3.2   France
           11.5.3.3   Italy
           11.5.3.4   Spain
           11.5.3.5   United Kingdom
       11.5.4   Japan
       11.5.5   China
12   United States Neuroblastoma Market (2017-2032)
   12.1   United States Neuroblastoma Market Historical Value (2017-2023)
   12.2   United States Neuroblastoma Market Forecast Value (2024-2032)
   12.3   United States Neuroblastoma Market (2017-2032) by Diagnosis
       12.3.1   Market Overview
       12.3.2   MIBG Scan
       12.3.3   Imaging
       12.3.4   Biopsy
   12.4   United States Neuroblastoma Market (2017-2032) by Treatment
       12.4.1   Market Overview
       12.4.2   Medication
       12.4.3   Surgery
       12.4.4   Chemotherapy
       12.4.5   Radiation Therapy
       12.4.6   Stem cell transplantation
       12.4.7   Immunotherapy
       12.4.8   Monoclonal Antibody Treatment
13   EU-4 and United Kingdom Neuroblastoma Market (2017-2032)
   13.1   EU-4 and United Kingdom Neuroblastoma Market Historical Value (2017-2023)
   13.2   EU-4 and United Kingdom Neuroblastoma Market Forecast Value (2024-2032)
   13.3   EU-4 and United Kingdom Neuroblastoma Market (2017-2032) by Diagnosis
       13.3.1   Market Overview
       13.3.2   MIBG Scan
       13.3.3   Imaging
       13.3.4   Biopsy
   13.4   EU-4 and United Kingdom Neuroblastoma Market (2017-2032) by Treatment
       13.4.1   Market Overview
       13.4.2   Medication
       13.4.3   Surgery
       13.4.4   Chemotherapy
       13.4.5   Radiation Therapy
       13.4.6   Stem cell transplantation
       13.4.7   Immunotherapy
       13.4.8   Monoclonal Antibody Treatment
14   Japan Neuroblastoma Market (2017-2032)
   14.1   Japan Neuroblastoma Market Historical Value (2017-2023)
   14.2   Japan Neuroblastoma Market Forecast Value (2024-2032)
   14.3   Japan Neuroblastoma Market (2017-2032) by Diagnosis
       14.3.1   Market Overview
       14.3.2   MIBG Scan
       14.3.3   Imaging
       14.3.4   Biopsy
   14.4   Japan Neuroblastoma Market (2017-2032) by Treatment
       14.4.1   Market Overview
       14.4.2   Medication
       14.4.3   Surgery
       14.4.4   Chemotherapy
       14.4.5   Radiation Therapy
       14.4.6   Stem cell transplantation
       14.4.7   Immunotherapy
       14.4.8   Monoclonal Antibody Treatment
15   China Neuroblastoma Market (2017-2032)
   15.1   China Neuroblastoma Market Historical Value (2017-2023)
   15.2   China Neuroblastoma Market Forecast Value (2024-2032)
   15.3   China Neuroblastoma Market (2017-2032) by Diagnosis
       15.3.1   Market Overview
       15.3.2   MIBG Scan
       15.3.3   Imaging
       15.3.4   Biopsy
   15.4   China Neuroblastoma Market (2017-2032) by Treatment
       15.4.1   Market Overview
       15.4.2   Medication
       15.4.3   Surgery
       15.4.4   Chemotherapy
       15.4.5   Radiation Therapy
       15.4.6   Stem cell transplantation
       15.4.7   Immunotherapy
       15.4.8   Monoclonal Antibody Treatment
16   Regulatory Framework
   16.1.1   US FDA
   16.1.2   EU EMA
   16.1.3   JAPAN PMDA
   16.1.4   Others
17   Patent Analysis
   17.1   Analysis by Type of Patent
   17.2   Analysis by Publication year
   17.3   Analysis by Issuing Authority
   17.4   Analysis by Patent Age
   17.5   Analysis by CPC Analysis
   17.6   Analysis by Patent Valuation
   17.7   Analysis by Key Players
18   Grants Analysis
   18.1   Analysis by Year
   18.2   Analysis by Amount Awarded
   18.3   Analysis by Issuing Authority
   18.4   Analysis by Grant Application
   18.5   Analysis by Funding Institute
   18.6   Analysis by NIH Departments
   18.7   Analysis by Recipient Organization
19   Clinical Trials Analysis
   19.1   Analysis by Trial Registration Year
   19.2   Analysis by Trial Status
   19.3   Analysis by Trial Phase
   19.4   Analysis by Therapeutic Area
   19.5   Analysis by Geography
20   Funding and Investment Analysis
   20.1   Analysis by Funding Instances
   20.2   Analysis by Type of Funding
   20.3   Analysis by Funding Amount
   20.4   Analysis by Leading Players
   20.5   Analysis by Leading Investors
   20.6   Analysis by Geography
21   Partnership and Collaboration Analysis
   21.1   Analysis by Partnership Instances
   21.2   Analysis by Type of Partnership
   21.3   Analysis by Leading Players
   21.4   Analysis by Geography
22   Supplier Landscape
   22.1   Eli Lilly and Company
       22.1.1   Financial Analysis
       22.1.2   Product Portfolio
       22.1.3   Demographic Reach and Achievements
       22.1.4   Mergers and Acquisition
       22.1.5   Certifications
   22.2   Bayer AG
       22.2.1   Financial Analysis
       22.2.2   Product Portfolio
       22.2.3   Demographic Reach and Achievements
       22.2.4   Mergers and Acquisition
       22.2.5   Certifications
   22.3   GE Healthcare
       22.3.1   Financial Analysis
       22.3.2   Product Portfolio
       22.3.3   Demographic Reach and Achievements
       22.3.4   Mergers and Acquisition
       22.3.5   Certifications
   22.4   Beckman Coulter Inc
       22.4.1   Financial Analysis
       22.4.2   Product Portfolio
       22.4.3   Demographic Reach and Achievements
       22.4.4   Mergers and Acquisition
       22.4.5   Certifications
   22.5   bioMerieux
       22.5.1   Financial Analysis
       22.5.2   Product Portfolio
       22.5.3   Demographic Reach and Achievements
       22.5.4   Mergers and Acquisition
       22.5.5   Certifications
   22.6   BD Biosciences
       22.6.1   Financial Analysis
       22.6.2   Product Portfolio
       22.6.3   Demographic Reach and Achievements
       22.6.4   Mergers and Acquisition
       22.6.5   Certifications
   22.7   Lonza Biologics Ltd
       22.7.1   Financial Analysis
       22.7.2   Product Portfolio
       22.7.3   Demographic Reach and Achievements
       22.7.4   Mergers and Acquisition
       22.7.5   Certifications
   22.8   Sanofi S.A.
       22.8.1   Financial Analysis
       22.8.2   Product Portfolio
       22.8.3   Demographic Reach and Achievements
       22.8.4   Mergers and Acquisition
       22.8.5   Certifications
   22.9   Pfizer Inc.
       22.9.1   Financial Analysis
       22.9.2   Product Portfolio
       22.9.3   Demographic Reach and Achievements
       22.9.4   Mergers and Acquisition
       22.9.5   Certifications
   22.10   Cellectar Biosciences
       22.10.1   Financial Analysis
       22.10.2   Product Portfolio
       22.10.3   Demographic Reach and Achievements
       22.10.4   Mergers and Acquisition
       22.10.5   Certifications
   22.11   Baxter International Inc.
       22.11.1   Financial Analysis
       22.11.2   Product Portfolio
       22.11.3   Demographic Reach and Achievements
       22.11.4   Mergers and Acquisition
       22.11.5   Certifications
   22.12   APEIRON Biologics AG
       22.12.1   Financial Analysis
       22.12.2   Product Portfolio
       22.12.3   Demographic Reach and Achievements
       22.12.4   Mergers and Acquisition
       22.12.5   Certifications
   22.13   United Therapeutics Corporation
       22.13.1   Financial Analysis
       22.13.2   Product Portfolio
       22.13.3   Demographic Reach and Achievements
       22.13.4   Mergers and Acquisition
       22.13.5   Certifications
   22.14   Sartorious AG
       22.14.1   Financial Analysis
       22.14.2   Product Portfolio
       22.14.3   Demographic Reach and Achievements
       22.14.4   Mergers and Acquisition
       22.14.5   Certifications
   22.15   MacroGenics, Inc.
       22.15.1   Financial Analysis
       22.15.2   Product Portfolio
       22.15.3   Demographic Reach and Achievements
       22.15.4   Mergers and Acquisition
       22.15.5   Certifications
23   Neuroblastoma Market - Distribution Model (Additional Insight)
   23.1   Overview
   23.2   Potential Distributors
   23.3   Key Parameters for Distribution Partner Assessment
24   Key Opinion Leaders (KOL) Insights (Additional Insight)
25   Company Competitiveness Analysis (Additional Insight)
   25.1   Very Small Companies
   25.2   Small Companies
   25.3   Mid-Sized Companies
   25.4   Large Companies
   25.5   Very Large Companies
26   Payment Methods (Additional Insight)
   26.1   Government Funded
   26.2   Private Insurance
   26.3   Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Key Questions Answered in the Report

What is the neuroblastoma market forecast outlook for 2024-2032?

The market is anticipated to grow at a CAGR of 2.4% during the forecast period of 2024-2032, driven by increasing prevalence of cancer across the major markets.

What are the major factors aiding the neuroblastoma market demand?

The market demand is driven by growth in clinical trials and research initiatives, emphasis on early detection of cancer and rising public private sector collaborations to drive awareness.

What are the major neuroblastoma market trends?

The adoption of gene therapies to offer personalised and accurate treatment to patients is a major market trend. In November 2023, the University of Texas researchers developed a gene therapy to pre-treat neuroblastoma tumors by expanding blood vessels surrounding it.

What is market segmentation based on diagnosis?

Based on diagnosis, the market is divided into MIBG scan, imaging, and biopsy.

Who are the major end users in the market?

Major end users include hospitals, specialty clinics, surgical centres, diagnostic centres, and others.

What type of treatments are present in the market?

Medication, surgery, chemotherapy, radiation therapy, stem cell transplantation, immunotherapy, and monoclonal antibody treatment are common treatments used to treat neuroblastoma.

What are the major regional markets for neuroblastoma, according to the EMR report?

The major regions of the market include the United States, Japan, China, EU-4, and the United Kingdom. EU-4 includes Germany, France, Italy, and Spain.

Who are the key players involved in the neuroblastoma market?

Key players involved in the market are Eli Lilly and Company, Bayer AG, GE Healthcare, Beckman Coulter Inc., bioMerieux, BD Biosciences, Lonza Biologics Ltd., Sanofi S.A., Pfizer Inc., Cellectar Biosciences, Baxter International Inc., APEIRON Biologics AG, United Therapeutics Corporation, Sartorious AG and MacroGenics, Inc.

Request Sample

Purchase Full Report

Mini Report

$ ~~2969~~ $2699

Selected Sections, One User
Printing Not Allowed
Email Delivery in PDF
~~Free Limited Customisation~~
~~Post Sales Analyst Support~~
~~50% Discount on Next Update~~

Buy Now

Single User License

$ ~~5499~~ $4999

All Sections, One User
One Print Allowed
Email Delivery in PDF
~~Free Limited Customisation~~
~~Post Sales Analyst Support~~
~~50% Discount on Next Update~~

Buy Now

Five User License

$ ~~6599~~ $5999

All Sections, Five Users
Five Prints Allowed
Email Delivery in PDF
Free Limited Customisation
Post Sales Analyst Support
~~50% Discount on Next Update~~

Buy Now

Corporate License

$ ~~7699~~ $6999

All Sections, Unlimited Users
Unlimited Prints Allowed
Email Delivery in PDF + Excel
Free Limited Customisation
Post Sales Analyst Support
50% Discount on Next Update

Buy Now

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation

Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER